Hormonal
Once-weekly subcutaneous semaglutide (up to 1.0 mg) in patients with type 2 diabetes produces significant weight loss (-4.69 kg at 6 months, -5.38 kg at 12 months) and improves metabolic parameters, but this weight loss is accompanied by a significant reduction in lean body mass (over 3 kg) that requires mitigation through nutritional education and structured exercise.
If you are using once-weekly semaglutide for Type 2 Diabetes, expect to lose about 5 kg of body weight over 6-12 months, along with improvements in blood sugar and blood pressure. However, this weight loss includes a significant loss of muscle mass (over 3 kg). To counteract this, you must actively engage in resistance exercise and follow a nutrition plan that prioritizes protein, as the medication alone will not preserve your muscle.
After 6 months from semaglutide initiation, body weight significantly decrease by -4.69 Kg... After 12 months, body weight was further reduced (-5.38 Kg)... lean mass was also significantly reduced by over 3 Kg both at 6 and 12 months... Loss of lean mass associated with weight loss warrants attention; parallel strategies to preserve skeletal muscle and improve physical function, i.e. nutritional education and structured exercise, are of great importance.
Why this rating
Observational, single-center, real-world study without a control group; results align with pivotal trials but lack randomization.
Source
Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice
Paola Pantanetti et al. · Frontiers in Endocrinology · 2024
DOI 10.3389/fendo.2024.1394506
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →